Biofrontera AG
Biofrontera AG
Hemmelrather Weg 201
D-51377 Leverkusen
Germany
Phone: +49 (214) 87632 66Website: https://biofrontera.com/en/
Latest news
- FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
7 October 2024 - Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz
10 October 2023 - Biofrontera Announces U.S. FDA Approval of Ameluz and Activating BF-RhodoLED Device for Treatment of Actinic Keratosis
11 May 2016 - FDA Accepts Filing of Ameluz and BFRhodoLED New Drug Application
11 September 2015 - Biofrontera Submits New Drug Application for Ameluz to FDA
13 July 2015
Drugs Associated with Biofrontera AG
Biofrontera AG manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Ameluz
Generic name: aminolevulinic acid Drug class: topical photochemotherapeutics |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||